Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303037 | 0.90 | WNT3A (0.82) | WNT3APORCN | |
| SCHEMBL12303105 | 0.89 | WNT3A (0.81) | WNT3APORCN | |
| SCHEMBL1723640 | 0.89 | WNT3A (1.00) | WNT3APORCN | |
| Wnt-974 SCHEMBL29351311 | 0.89 | WNT3A (1.00) | WNT3APORCN | |
| Wnt-974 SCHEMBL29382356 | 0.89 | WNT3A (1.00) | WNT3APORCN | |
| Wnt-974 SCHEMBL1723611 | 0.89 | WNT3A (1.00) | WNT3APORCN | |
| SCHEMBL1724108 | 0.89 | WNT3A (1.00) | WNT3APORCN | |
| SCHEMBL12303045 | 0.87 | WNT3A (0.83) | WNT3APORCN | |
| SCHEMBL1722861 | 0.87 | WNT3A (1.00) | WNT3A | |
| SCHEMBL1725533 | 0.87 | WNT3A (1.00) | WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3693476-B1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS AG (CH) | 2023-10-18 | — | — | EP | claimed |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION | 2021-02-25 | — | — | US | claimed |
| EP-3693476-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | Novartis AG (CH) | 2020-08-12 | — | — | EP | claimed |
| EP-2820151-B1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | claimed |
| US-20190203301-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-07-04 | — | — | US | claimed |
| US-20180153884-A1 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | CUREGENIX CORPORATION | 2018-06-07 | — | — | US | claimed |
| US-20180112273-A1 | TUMOR BIOMARKERS AND USE THEREOF | CUREGENIX CORPORATION | 2018-04-26 | — | — | US | claimed |
| EP-3302467-A1 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | Curegenix Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| EP-3302479-A1 | TUMOR BIOMARKERS AND USE THEREOF | Curegenix Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| US-20170306409-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-10-26 | — | — | US | claimed |
| US-20150125857-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | claimed |
| EP-2820151-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | Novartis AG (CH) | 2015-01-07 | — | — | EP | claimed |
| WO-2014141038-A2 | MARKERS ASSOCIATED WITH WNT INHIBITORS | IRM LLC (BM) | 2014-09-18 | — | — | WO | claimed |
| CN-102369187-B | N- (hetero) aryl, 2- (hetero) aryl substituted acetamides as WNT signal modulators | IRM LLC | 2014-06-04 | — | — | CN | claimed |
| EP-2403832-B1 | N-(HETERO)ARYL,2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2013-11-20 | — | — | EP | claimed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| WO-2013130364-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | claimed |
| EP-2403832-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2012-01-11 | — | — | EP | claimed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | claimed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125857-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | WNT3, WNT3A, DKK1 | WNT3A 2/4885PORCN 2382/4885 |
| US-20190203301-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | WNT3, WNT3A, DKK1 | WNT3A 2/4885PORCN 2382/4885 |
| US-20180153884-A1 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY | WNT1, CTNNB1, WNT3 | WNT3A 4/4885PORCN 3182/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | WNT3A 3/4885PORCN 2999/4885 |
| US-20170306409-A1 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | WNT3, WNT3A, DKK1 | WNT3A 2/4885PORCN 2382/4885 |
| US-20210054466-A1 | TUMOR BIOMARKERS AND USE THEREOF | CTNNB1, CTNNBL1, WNT1 | WNT3A 9/4885PORCN 3611/4885 |
| US-20180112273-A1 | TUMOR BIOMARKERS AND USE THEREOF | CTNNB1, CTNNBL1, WNT1 | WNT3A 9/4885PORCN 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.